Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
boston blog main
deals
8
×
life sciences
national blog main
san francisco blog main
san francisco top stories
8
×
boston top stories
national top stories
biotech
boston
clinical trials
new york blog main
new york top stories
startups
eli lilly
ipo
sanofi
vc
boehringer ingelheim
cancer
crispr
fda
genentech
indiana blog main
indiana top stories
investing
roche
san diego blog main
san diego top stories
san francisco
sickle cell disease
third rock ventures
venture capital
warp drive bio
wisconsin blog main
wisconsin top stories
abbvie
acetylon pharmaceuticals
akouos
alexion pharmaceuticals
What
medicines
8
×
deal
bio
cancer
new
biotech
companies
diseases
drug
ipo
research
rna
startup
years
abandoning
acquisitions
ago
aiming
aims
ambys
announced
approach
approval
baggage
based
bets
big
blueprint
called
candidate
ceo
collabs
comes
control
covid
create
crispr
currently
cut
cuts
Language
unset
Current search:
medicines
×
photo
×
" san francisco top stories "
×
deals
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines